Mosunetuzumab in DLBCL Shows Promise as Frontline Option for Elderly Patients

(MedPage Today) — At the recent American Society of Hematology (ASH) meeting, researchers presented early data from a phase II study evaluating mosunetuzumab (Lunsumio) as frontline monotherapy for elderly patients with diffuse large B-cell lymphoma…

Source link : https://www.medpagetoday.com/meetingcoverage/ashfuturefocusdlbcl/119036

Author :

Publish date : 2025-12-16 15:38:00

Copyright for syndicated content belongs to the linked Source.

M	T	W	T	F	S	S
						1
2	3	4	5	6	7	8
9	10	11	12	13	14	15
16	17	18	19	20	21	22
23	24	25	26	27	28

Mosunetuzumab in DLBCL Shows Promise as Frontline Option for Elderly Patients

Don’t Overlook Chikungunya: Prevention Tips for Physicians With Traveling Patients

AI Model Stratifies Late Recurrence Risk in HR-Positive Breast Cancer

Related Posts

AMA Calls for Government-Enforced Digital Interoperability

Why are fewer people donating their organs?

Self-Acupressure May Ease Fatigue in Ovarian Cancer

Fenofibrate: Effective in Children With High Triglycerides?

Seafarers were visiting remote Arctic islands over 4000 years ago

‘It’s Not Normal but It’s Not Really Abnormal’: What We Heard This Week

AMA Calls for Government-Enforced Digital Interoperability

Why are fewer people donating their organs?

Self-Acupressure May Ease Fatigue in Ovarian Cancer

Fenofibrate: Effective in Children With High Triglycerides?

Seafarers were visiting remote Arctic islands over 4000 years ago

‘It’s Not Normal but It’s Not Really Abnormal’: What We Heard This Week

Anti-Racist Care: A New Quality Metric?

Free of ‘Sports Prison,’ Winter Athletes Get Shot at Olympics Without COVID Lockdown

Categories

Archives